Brown Advisory, an investment management company, released its “Brown Large-Cap Growth Strategy” for the first-quarter 2026 investor letter. A copy of the letter is available to download here. The Brown Advisory Large-Cap Growth Strategy experienced a decline in the first quarter of 2026, modestly trailing the Russell 1000 Growth Index. Despite negative absolute returns amidst volatility, relative performance improved significantly as the quarter progressed. Initial pressures stemmed from weaknesses in the software sector, affected by concerns over AI disrupting traditional models. Conversely, sectors like Industrials and Consumer Discretionary positively contributed to performance, while Information Technology and Health Care were the largest detractors. The strategy’s ability to outperform in a down market indicates the quality of holdings. As market leadership broadens, the firm’s focus remains on maintaining a diversified portfolio of high-quality growth companies, aiming for strong long-term results. Please review the Strategy’s top five holdings to gain insights into their key selections for 2026.
In its first-quarter 2026 investor letter, Brown Advisory Large-Cap Growth Strategy highlighted Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a biopharmaceutical company that discovers and commercializes therapeutics based on ribonucleic acid interference. On July 2, 2026, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) closed at $312.78 per share, reflecting a market capitalization of $41.76 billion. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted a one-month return of 3.21%, while its shares lost 5.76% over the past 52 weeks.
Brown Advisory Large-Cap Growth Strategy stated the following regarding Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in its Q1 2026 investor letter:
“Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a leading developer of RNA interference (RNAi) therapeutics, with a growing portfolio of treatments targeting serious and underserved diseases. We initiated the position following a period of share price weakness, which we believe created an attractive entry point into a company that has demonstrated a repeatable ability to develop and commercialize novel therapies. We have followed and owned the company within our Mid-Cap Growth Strategy for several years. Alnylam’s expanding portfolio provides a durable revenue base, supported by continued patient identification and adoption across its core franchises. We believe the company’s differentiated platform and growing pipeline positions it well for sustained long-term growth.”
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 54 hedge fund portfolios held Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) at the end of the first quarter, compared to 67 in the previous quarter. In Q1 2026, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reported combined net product revenues of $1.036 billion, up 121% year-over-year and 4% compared to Q4 2025. While we acknowledge the risk and potential of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and shared the list of best fundamentally strong stocks to buy for long term. In addition, please check out our hedge fund investor letters Q1 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
